SC 109

Drug Profile

SC 109

Latest Information Update: 04 Jul 2000

Price : $50

At a glance

  • Originator Scotia Holdings [CEASED]
  • Class Antiasthmatics
  • Mechanism of Action Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Pulmonary fibrosis

Most Recent Events

  • 04 Jul 2000 Discontinued-II for Pulmonary fibrosis in United Kingdom (Unknown route)
  • 04 Jul 2000 Discontinued-II for Asthma in United Kingdom (Unknown route)
  • 11 Jul 1997 Phase-II clinical trials for Pulmonary fibrosis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top